company background image

Ipca Laboratories BSE:524494 Stock Report

Last Price


Market Cap







21 May, 2022


Company Financials +
524494 fundamental analysis
Snowflake Score
Future Growth3/6
Past Performance2/6
Financial Health6/6

524494 Stock Overview

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India.

Ipca Laboratories Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ipca Laboratories
Historical stock prices
Current Share Price₹989.00
52 Week High₹1,383.55
52 Week Low₹917.00
1 Month Change-4.11%
3 Month Change1.01%
1 Year Change-11.16%
3 Year Change112.06%
5 Year Change292.85%
Change since IPO1,176.13%

Recent News & Updates

Shareholder Returns

524494IN PharmaceuticalsIN Market

Return vs Industry: 524494 underperformed the Indian Pharmaceuticals industry which returned -9.6% over the past year.

Return vs Market: 524494 underperformed the Indian Market which returned 9.6% over the past year.

Price Volatility

Is 524494's price volatile compared to industry and market?
524494 volatility
524494 Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.3%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.8%

Stable Share Price: 524494 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 524494's weekly volatility (4%) has been stable over the past year.

About the Company

194914,574Premchand Godha

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including cardiology, gastroenterology, dermatology, rheumatology, urology, ophthalmology, infectious disease, immunosuppressant, probiotics, respiratory, allergy, nutraceuticals, anti-neoplastic, malarial, neurology, psychiatry, orthopedics, helminthics, fever, hematology, hepatoprotective, diabetology, anti-epileptic, emollients/protectives, NSAIDs, rheumatology, anti-arthritic, and neuropathic pain, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections.

Ipca Laboratories Fundamentals Summary

How do Ipca Laboratories's earnings and revenue compare to its market cap?
524494 fundamental statistics
Market Cap₹250.91b
Earnings (TTM)₹9.15b
Revenue (TTM)₹56.56b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524494 income statement (TTM)
Cost of Revenue₹20.95b
Gross Profit₹35.61b
Other Expenses₹26.45b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 25, 2022

Earnings per share (EPS)36.07
Gross Margin62.95%
Net Profit Margin16.18%
Debt/Equity Ratio5.7%

How did 524494 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Ipca Laboratories undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: 524494 (₹989) is trading above our estimate of fair value (₹642.83)

Significantly Below Fair Value: 524494 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 524494 is poor value based on its PE Ratio (27.4x) compared to the Indian Pharmaceuticals industry average (21.9x).

PE vs Market: 524494 is poor value based on its PE Ratio (27.4x) compared to the Indian market (20.5x).

Price to Earnings Growth Ratio

PEG Ratio: 524494 is poor value based on its PEG Ratio (1.5x)

Price to Book Ratio

PB vs Industry: 524494 is overvalued based on its PB Ratio (4.8x) compared to the IN Pharmaceuticals industry average (2.6x).

Future Growth

How is Ipca Laboratories forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

Future Growth Score


Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 524494's forecast earnings growth (18.2% per year) is above the savings rate (6.7%).

Earnings vs Market: 524494's earnings (18.2% per year) are forecast to grow faster than the Indian market (17.5% per year).

High Growth Earnings: 524494's earnings are forecast to grow, but not significantly.

Revenue vs Market: 524494's revenue (12.1% per year) is forecast to grow faster than the Indian market (11.8% per year).

High Growth Revenue: 524494's revenue (12.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 524494's Return on Equity is forecast to be low in 3 years time (18.8%).

Past Performance

How has Ipca Laboratories performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524494 has high quality earnings.

Growing Profit Margin: 524494's current net profit margins (16.2%) are lower than last year (19.8%).

Past Earnings Growth Analysis

Earnings Trend: 524494's earnings have grown significantly by 29.2% per year over the past 5 years.

Accelerating Growth: 524494's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524494 had negative earnings growth (-14%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.4%).

Return on Equity

High ROE: 524494's Return on Equity (17.2%) is considered low.

Financial Health

How is Ipca Laboratories's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524494's short term assets (₹39.6B) exceed its short term liabilities (₹12.9B).

Long Term Liabilities: 524494's short term assets (₹39.6B) exceed its long term liabilities (₹2.1B).

Debt to Equity History and Analysis

Debt Level: 524494 has more cash than its total debt.

Reducing Debt: 524494's debt to equity ratio has reduced from 31.3% to 5.7% over the past 5 years.

Debt Coverage: 524494's debt is well covered by operating cash flow (278.8%).

Interest Coverage: 524494 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet


What is Ipca Laboratories's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 524494's dividend (0.4%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 524494's dividend (0.4%) is low compared to the top 25% of dividend payers in the Indian market (1.59%).

Stability and Growth of Payments

Stable Dividend: 524494's dividend payments have been volatile in the past 10 years.

Growing Dividend: 524494's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (11.1%), 524494's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (27.2%), 524494's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Premchand Godha (75 yo)

no data




Mr. Premchand Godha, CA, B.Com., A.C.A., has been the Managing Director of Ipca Laboratories Limited since 1983 and serves as its Chief Executive Officer. Mr. Godha was in professional practice for five ye...

CEO Compensation Analysis

Compensation vs Market: Premchand's total compensation ($USD1.39M) is above average for companies of similar size in the Indian market ($USD610.51K).

Compensation vs Earnings: Premchand's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: 524494's board of directors are seasoned and experienced ( 11.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: 524494 insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Ipca Laboratories Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Ipca Laboratories Limited
  • Ticker: 524494
  • Exchange: BSE
  • Founded: 1949
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹250.913b
  • Shares outstanding: 253.70m
  • Website:

Number of Employees


  • Ipca Laboratories Limited
  • 125, Kandivli Industrial Estate
  • Kandivli (West)
  • Mumbai
  • Maharashtra
  • 400067
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Annual Earnings2021/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.